Laroxyl (Amitriptyline Hydrochloride)

Laroxyl, a tricyclic antidepressant, is indicated for several conditions affecting mood, pain pathways and vascular headaches.

• Major depressive disorder: alleviates depressive symptoms and improves mood in adults.
• Neuropathic pain: reduces pain intensity associated with peripheral nerve injury.
• Migraine prophylaxis: decreases frequency and severity of migraine attacks.
• Chronic tension‑type headache: lessens headache days and associated discomfort.

• Amitriptyline Hydrochloride inhibits the reuptake of norepinephrine and serotonin, increasing their synaptic concentrations. It also antagonizes muscarinic, histaminergic, and alpha‑adrenergic receptors, contributing to its analgesic, antihistaminic, and anticholinergic effects while modulating central pain pathways and mood regulation.

Amitriptyline may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Dry mouth: reduced salivary secretion.
• Drowsiness: increased sedation, especially after dosing.
• Constipation: slowed gastrointestinal motility.
• Weight gain: increased appetite and caloric intake.
• Blurred vision: temporary visual disturbances.
• Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening.
• Seizures: heightened risk in predisposed individuals.
• Severe hypotension: sudden drop in blood pressure.
• Agranulocytosis: marked reduction in white blood cells.
• Suicidal thoughts: emergence of suicidal ideation, especially early in treatment.

When prescribing Laroxyl, clinicians should consider several safety measures to minimize risk.

• Assess cardiac history: obtain baseline ECG in patients with known heart disease.
• Monitor for suicidal ideation: closely observe patients during the initial treatment phase.
• Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal.
• Caution in elderly: increased sensitivity to anticholinergic and sedative effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amitriptyline can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis.
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): potential serotonin syndrome.
• Linezolid: additive serotonergic activity.
• Tramadol: increased risk of seizures and serotonin syndrome.
• Other serotonergic agents: heightened serotonin toxicity.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs: amplified anticholinergic burden.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation.
• CYP2D6 inhibitors (e.g., fluoxetine, quinidine): increased amitriptyline plasma levels.
• Antihypertensive agents: additive hypotensive effect.
• Diuretics: potential electrolyte disturbances.